Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMX | P51813 | 2/20 | 0.57 |
| ▸ | BRAF | P15056 | 10/20 | 0.57 |
| ▸ | CSF1R | P07333 | 3/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.56 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.54 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.54 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.54 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18181677 | 0.89 | BMX (0.57) | BMXBRAFCSF1RKITDDR2 | |
| SCHEMBL16011472 | 0.82 | BMX (0.49) | BMXBRAFCSF1RKITDDR2 | |
| SCHEMBL17208652 | 0.80 | PIKFYVE (0.56) | BRAFCSF1RKITDDR2DDR1 | |
| SCHEMBL29541039 | 0.80 | KCNQ3 (0.49) | BMXBRAFCSF1RKITDDR2 | |
| SCHEMBL24274784 | 0.80 | KCNQ3 (0.49) | BMXBRAFCSF1RKITDDR2 | |
| SCHEMBL22145723 | 0.79 | BRAF (0.67) | BMXBRAFCSF1RKITDDR2 | |
| SCHEMBL24275050 | 0.79 | BMX (0.48) | BMXBRAFCSF1RKITDDR2 | |
| SCHEMBL29540913 | 0.79 | BMX (0.48) | BMXBRAFCSF1RKITDDR2 | |
| SCHEMBL18874263 | 0.78 | BRAF (0.68) | BRAF | |
| SCHEMBL19073209 | 0.78 | BRAF (0.73) | BRAFCSF1RKITABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014138485-A1 | EX VIVO PRODUCTION OF PLATELETS FROM HEMATOPOIETIC STEM CELLS AND THE PRODUCT THEREOF | IRM LLC (BM) | 2014-09-12 | — | — | WO | disclosed |
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-7642255-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-01-05 | — | — | US | disclosed |
| EP-1651648-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-02 | — | — | EP | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| EP-1899344-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM, LLC (BM) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006135824-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM LLC (BM) | 2006-12-21 | — | — | WO | disclosed |
| EP-1651648-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-03 | — | — | EP | disclosed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | disclosed |
| WO-2005011597-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | LIFR, ALPG, BMI1 | BMX 3235/4885BRAF 2097/4885CSF1R 1212/4885 |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | BMX, FES, FRK | BMX 1/4885BRAF 67/4885CSF1R 453/4885 |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BMX, FES, FRK | BMX 1/4885BRAF 67/4885CSF1R 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.